JP2023175957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023175957A5 JP2023175957A5 JP2023174374A JP2023174374A JP2023175957A5 JP 2023175957 A5 JP2023175957 A5 JP 2023175957A5 JP 2023174374 A JP2023174374 A JP 2023174374A JP 2023174374 A JP2023174374 A JP 2023174374A JP 2023175957 A5 JP2023175957 A5 JP 2023175957A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- cancer
- inhibitors
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025156045A JP2025186428A (ja) | 2018-04-13 | 2025-09-19 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/953,108 US20180228907A1 (en) | 2014-04-14 | 2018-04-13 | Cereblon ligands and bifunctional compounds comprising the same |
| US15/953,108 | 2018-04-13 | ||
| PCT/US2019/026570 WO2019199816A1 (en) | 2018-04-13 | 2019-04-09 | Cereblon ligands and bifunctional compounds comprising the same |
| JP2020555835A JP2021521192A (ja) | 2018-04-13 | 2019-04-09 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555835A Division JP2021521192A (ja) | 2018-04-13 | 2019-04-09 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156045A Division JP2025186428A (ja) | 2018-04-13 | 2025-09-19 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023175957A JP2023175957A (ja) | 2023-12-12 |
| JP2023175957A5 true JP2023175957A5 (https=) | 2025-05-16 |
| JP7748432B2 JP7748432B2 (ja) | 2025-10-02 |
Family
ID=66248825
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555835A Pending JP2021521192A (ja) | 2018-04-13 | 2019-04-09 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
| JP2023174374A Active JP7748432B2 (ja) | 2018-04-13 | 2023-10-06 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
| JP2025156045A Pending JP2025186428A (ja) | 2018-04-13 | 2025-09-19 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555835A Pending JP2021521192A (ja) | 2018-04-13 | 2019-04-09 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156045A Pending JP2025186428A (ja) | 2018-04-13 | 2025-09-19 | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3774772A1 (https=) |
| JP (3) | JP2021521192A (https=) |
| KR (1) | KR20210003804A (https=) |
| CN (2) | CN112262134B (https=) |
| AU (3) | AU2019251223A1 (https=) |
| CA (1) | CA3095912A1 (https=) |
| IL (3) | IL302595A (https=) |
| MX (2) | MX2020010571A (https=) |
| WO (1) | WO2019199816A1 (https=) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3807272A1 (en) | 2018-06-13 | 2021-04-21 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| US12186401B2 (en) | 2019-03-01 | 2025-01-07 | Ontario Institute for Cancer Research (OICR) and Sinai Health System | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11890346B2 (en) * | 2019-06-12 | 2024-02-06 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| KR20220054347A (ko) * | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP7852923B2 (ja) | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス．エー． | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
| US20230099031A1 (en) * | 2019-12-17 | 2023-03-30 | Orionis Biosciences, Inc. | Bifunctional agents for protein recruitment and/or degradation |
| PH12022551482A1 (en) * | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| US20230123104A1 (en) * | 2020-03-06 | 2023-04-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of tricyclic compound acting on crbn protein and preparation method therefor |
| EP4122925A4 (en) * | 2020-03-17 | 2024-04-17 | Medshine Discovery Inc. | Proteolysis regulator and method for using same |
| JP7644139B2 (ja) | 2020-03-21 | 2025-03-11 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| WO2021194878A1 (en) | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Selective modulators of mutant lrrk2 proteolysis and associated methods of use |
| CN113582974B (zh) * | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
| JP2023530030A (ja) | 2020-06-19 | 2023-07-12 | シーフォー セラピューティクス， インコーポレイテッド | Ｂｒａｆ分解剤 |
| CN115916769B (zh) * | 2020-06-28 | 2024-09-10 | 深圳扬厉医药技术有限公司 | 并环吲唑类化合物 |
| CN115697992B (zh) * | 2020-07-09 | 2025-09-19 | 西藏海思科制药有限公司 | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 |
| CN114341128B (zh) * | 2020-07-24 | 2024-06-25 | 恩瑞生物医药科技（上海）有限公司 | 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途 |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| WO2022048605A1 (zh) * | 2020-09-04 | 2022-03-10 | 南昌奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
| CN114262319B (zh) * | 2020-12-01 | 2023-05-05 | 南昌奥瑞药业有限公司 | 一类双功能分子、其制备方法及其应用 |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| AU2021401580A1 (en) * | 2020-12-14 | 2023-06-22 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN112679338A (zh) * | 2020-12-28 | 2021-04-20 | 丽珠集团新北江制药股份有限公司 | 一种制备噁唑啉杀虫剂阿福拉纳中间体的方法 |
| CN112707809B (zh) * | 2020-12-30 | 2023-08-29 | 丽珠集团新北江制药股份有限公司 | 一种制备噁唑啉杀虫剂氟雷拉纳中间体的方法 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022166879A1 (zh) * | 2021-02-04 | 2022-08-11 | 正大天晴药业集团股份有限公司 | 苯并七元环类双功能化合物及其应用 |
| JP2024512501A (ja) | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| CA3211378A1 (en) * | 2021-03-29 | 2022-10-06 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine |
| CN115141179B (zh) * | 2021-03-31 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| TW202309039A (zh) | 2021-05-05 | 2023-03-01 | 美商百健Ｍａ公司 | 用於靶向布魯頓氏酪胺酸激酶降解之化合物 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| US20250018046A1 (en) | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| EP4367113A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
| CA3226162A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| CA3227425A1 (en) * | 2021-07-26 | 2023-02-02 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound |
| TW202321219A (zh) * | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | 雜環衍生物及其組合物和藥學上的應用 |
| CN115746058A (zh) * | 2021-09-03 | 2023-03-07 | 南京知和医药科技有限公司 | 一种多环化合物在制备抗肿瘤药物方面的用途 |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| CN114516810B (zh) * | 2022-01-18 | 2023-12-26 | 浙江奥翔药业股份有限公司 | 制备药物中间体2-氨基-4-羟基苯甲酸的方法 |
| CN114085213B (zh) * | 2022-01-20 | 2022-03-25 | 苏州国匡医药科技有限公司 | 一种arv-471的制备方法 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
| WO2024006776A1 (en) | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Estrogen receptor alpha degraders and medical use thereof |
| JP2025521686A (ja) | 2022-06-27 | 2025-07-10 | リレー セラピューティクス， インコーポレイテッド | エストロゲン受容体アルファ分解剤及びその使用 |
| AU2023300784A1 (en) * | 2022-06-30 | 2025-01-02 | Anhorn Medicines Co., Ltd. | Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same |
| US20260028354A1 (en) * | 2022-07-12 | 2026-01-29 | Regent Of The University Of Michigan | Tetrahydronaphthalene derivatives as estrogen receptor degraders |
| EP4574823A1 (en) * | 2022-08-17 | 2025-06-25 | Korea Research Institute of Chemical Technology | Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof |
| CN115403561B (zh) * | 2022-08-22 | 2024-03-08 | 西安交通大学 | 一种基于沙利度胺类似物的细胞内自组装蛋白降解剂及其制备方法和应用 |
| WO2024054955A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| CN119998300A (zh) * | 2022-09-29 | 2025-05-13 | 海南先声再明医药股份有限公司 | 一类稠环化合物及其用途 |
| JP2025533592A (ja) * | 2022-09-29 | 2025-10-07 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法 |
| CN117801051A (zh) * | 2022-09-30 | 2024-04-02 | 苏州德亘生物医药有限公司 | 一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物 |
| CN119998290A (zh) | 2022-10-03 | 2025-05-13 | 公立大学法人横滨市立大学 | 具有二环性结构的咪唑并吡啶衍生物 |
| CN116751186B (zh) * | 2022-12-23 | 2024-10-18 | 南京知和医药科技有限公司 | 一种雌激素受体调节剂的制备及其用途 |
| TWI882643B (zh) * | 2023-01-16 | 2025-05-01 | 大陸商南京明德新藥研發有限公司 | 取代的苯並七元環化合物及其應用 |
| CN120569372A (zh) | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| CN116253719B (zh) * | 2023-03-06 | 2025-04-01 | 苏州国匡医药科技有限公司 | 一种雌激素和雄激素受体双重降解剂及其应用 |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| WO2024226422A1 (en) * | 2023-04-22 | 2024-10-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Helicase degraders |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| CN121263412A (zh) * | 2023-06-01 | 2026-01-02 | 上海海和药物研究开发股份有限公司 | 用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物 |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| WO2025056074A1 (zh) * | 2023-09-14 | 2025-03-20 | 中国科学院上海药物研究所 | 杂环基取代的吲唑酮类化合物、其制备方法、药物组合物及其应用 |
| TW202515874A (zh) | 2023-09-28 | 2025-04-16 | 美商亞文納營運公司 | 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物 |
| TW202530189A (zh) | 2023-09-29 | 2025-08-01 | 日商第一三共股份有限公司 | ３－苯基丙基胺衍生物 |
| WO2025081092A1 (en) * | 2023-10-12 | 2025-04-17 | Kolm Therapeutics Inc. | Bifunctional androgen receptor compounds |
| WO2025129172A1 (en) * | 2023-12-14 | 2025-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Crbn molecular glue degraders and uses thereof |
| WO2025136129A1 (en) * | 2023-12-22 | 2025-06-26 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025245032A1 (en) * | 2024-05-20 | 2025-11-27 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound |
| WO2026060321A1 (en) | 2024-09-13 | 2026-03-19 | Olema Pharmaceuticals, Inc. | Kat6 degrader compounds and method thereof |
| GB202414342D0 (en) * | 2024-09-30 | 2024-11-13 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| AU2013283378B2 (en) | 2012-06-25 | 2017-07-13 | Oncoethix Gmbh | Method of treating lymphoma using thienotriazolodiazepine compounds |
| WO2014128111A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
| ES2648876T3 (es) | 2013-07-23 | 2018-01-08 | Bayer Pharma Aktiengesellschaft | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
| CN110627770A (zh) | 2013-11-18 | 2019-12-31 | 福马疗法公司 | 作为bet溴域抑制剂的四氢喹啉组成物 |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| JP6351306B2 (ja) | 2014-03-06 | 2018-07-04 | キヤノン株式会社 | 画像処理装置、画像処理装置の制御方法およびプログラム |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2015195863A1 (en) | 2014-06-20 | 2015-12-23 | Constellation Pharmaceuticals, Inc. | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| CA2960090A1 (en) | 2014-10-02 | 2016-04-07 | Glaxosmithkline Intellectual Property (No.2) Limited | Compound |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CA3036841A1 (en) * | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| CA3036834A1 (en) * | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| BR112019011200B1 (pt) * | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| KR20250117470A (ko) * | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| BR112019015312A2 (pt) * | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2018226542A1 (en) * | 2017-06-09 | 2018-12-13 | Arvinas, Inc. | Modulators of proteolysis and associated methods of use |
| ES2965049T3 (es) * | 2017-07-12 | 2024-04-10 | Dana Farber Cancer Inst Inc | Compuestos para la degradación de la proteína tau |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN109422733A (zh) * | 2017-09-03 | 2019-03-05 | 上海美志医药科技有限公司 | 一类抑制并降解酪氨酸蛋白激酶alk的化合物 |
| WO2019148055A1 (en) * | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
-
2019
- 2019-04-09 IL IL302595A patent/IL302595A/en unknown
- 2019-04-09 CN CN201980036235.7A patent/CN112262134B/zh active Active
- 2019-04-09 CN CN202410558602.2A patent/CN118480030A/zh active Pending
- 2019-04-09 WO PCT/US2019/026570 patent/WO2019199816A1/en not_active Ceased
- 2019-04-09 CA CA3095912A patent/CA3095912A1/en active Pending
- 2019-04-09 MX MX2020010571A patent/MX2020010571A/es unknown
- 2019-04-09 EP EP19719093.7A patent/EP3774772A1/en active Pending
- 2019-04-09 IL IL310860A patent/IL310860A/en unknown
- 2019-04-09 AU AU2019251223A patent/AU2019251223A1/en not_active Abandoned
- 2019-04-09 KR KR1020207032733A patent/KR20210003804A/ko active Pending
- 2019-04-09 JP JP2020555835A patent/JP2021521192A/ja active Pending
-
2020
- 2020-10-07 MX MX2023002134A patent/MX2023002134A/es unknown
- 2020-10-11 IL IL277934A patent/IL277934A/en unknown
-
2023
- 2023-10-06 JP JP2023174374A patent/JP7748432B2/ja active Active
- 2023-10-10 AU AU2023248067A patent/AU2023248067B2/en active Active
-
2025
- 2025-09-19 JP JP2025156045A patent/JP2025186428A/ja active Pending
- 2025-12-03 AU AU2025275145A patent/AU2025275145A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023175957A5 (https=) | ||
| JP2021521192A5 (https=) | ||
| RU2020139890A (ru) | Имидные модуляторы протеолиза и способы их применения | |
| US12569464B2 (en) | Protein-protein interaction inducing technology | |
| JP7463308B2 (ja) | 標的タンパク質の分解向上のための化合物および方法 | |
| CA2861066C (en) | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase | |
| JP2017513862A5 (https=) | ||
| RU2018105094A (ru) | Модуляторы протеолиза на основе аланина и связанные с ними способы применения | |
| WO2019199621A4 (en) | Bi-functional molecules to degrade circulating proteins | |
| US10233213B2 (en) | Foldamer helix bundle-based molecular encapsulation | |
| JP2025509730A5 (https=) | ||
| RU2020136948A (ru) | Лиганды цереблона и содержащие их бифункциональные соединения | |
| RU2023100284A (ru) | Лиганды цереблона и бифункциональные соединения, содержащие их | |
| RU2019123462A (ru) | Лиганды цереблона и бифункциональные соединения, содержащие их | |
| TW202342442A (zh) | Ｒａｆ激酶抑制劑及其使用方法 | |
| US11285219B2 (en) | Peptide-oligourea hybrid compounds | |
| RU2022126566A (ru) | Соединения и способы для улучшенного расщепления специфических белков | |
| JP2025509736A5 (https=) | ||
| HK40023141A (en) | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase | |
| BR122021002241B1 (pt) | Composto bifuncional, composto, composição farmacêutica, e, uso de um composto para preparar um medicamento | |
| BR112017019751B1 (pt) | Composto bifuncional, composição farmacêutica, e, uso de um composto para preparar um medicamento |